Exact Mass: 524.3209833999999
Exact Mass Matches: 524.3209833999999
Found 339 metabolites which its exact mass value is equals to given mass value 524.3209833999999
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
VPGPR Enterostatin
C23H40N8O6 (524.3070660000001)
Enterostatin VPGPR (Val-Pro-Gly-Pro-Arg) is a pentapeptide released from procolipase during fat digestion. In addition to the pancreas, enterostatin-immunoreactive cells are also present in the antrum and proximal small intestine. Enterostatin selectively reduces fat intake, decreases insulin secretion, and also increases energy expenditure by activating brown adipose tissue during high-fat feeding. Enterostatins are pentapeptides derived from the NH2-terminus of procolipase after tryptic cleavage and belong to the family of gut-brain peptides. Enterostatin is generated by the action of trypsin on procolipase in the intestinal lumen. Its structure is highly conserved in evolution, with an amino acid sequence of XPXPR. Three enterostatin sequences, Val-Pro-Asp-Pro-Arg (VPDPR), Val-Pro-Gly-Pro-Arg (VPGPR), and Ala-Pro-Gly-Pro-Arg (APGPR), have been studied extensively and shown to be almost equally effective in their ability to decrease dietary fat preference. Enterostatins are selective inhibitors of appetite, particularly of fat intake. Hyperenterostatinemia in obesity is probably secondary to enterostatin resistance; therefore, the regulatory system is producing more enterostatin to counteract the resistance. This is very similar to hyperinsulinemia and hyperleptinemia in obesity. The diminution in the meal-induced secretion of enterostatin in obesity suggests a delay in the appearance of satiety, leading to increased caloric intake. In rats enterostatin decreases body weight by decreasing fat-calorie intake and increasing the sympathetic firing rate of the nerves in interscapular brown adipose tissue. Enterostatin levels are elevated in the plasma of obese women, and enterostatin secretion is diminished after satiety. Oral administration of enterostatin, however, has no effect on food intake, energy expenditure, or body weight in subjects with a preference for a high-fat diet experiencing a negative energy and fat balance, and the physiology of enterostatin in humans remains to be defined. (PMID: 10084574, 9526102, 8886249) [HMDB] Enterostatin VPGPR (Val-Pro-Gly-Pro-Arg) is a pentapeptide released from procolipase during fat digestion. In addition to the pancreas, enterostatin-immunoreactive cells are also present in the antrum and proximal small intestine. Enterostatin selectively reduces fat intake, decreases insulin secretion, and also increases energy expenditure by activating brown adipose tissue during high-fat feeding. Enterostatins are pentapeptides derived from the NH2-terminus of procolipase after tryptic cleavage and belong to the family of gut-brain peptides. Enterostatin is generated by the action of trypsin on procolipase in the intestinal lumen. Its structure is highly conserved in evolution, with an amino acid sequence of XPXPR. Three enterostatin sequences, Val-Pro-Asp-Pro-Arg (VPDPR), Val-Pro-Gly-Pro-Arg (VPGPR), and Ala-Pro-Gly-Pro-Arg (APGPR), have been studied extensively and shown to be almost equally effective in their ability to decrease dietary fat preference. Enterostatins are selective inhibitors of appetite, particularly of fat intake. Hyperenterostatinemia in obesity is probably secondary to enterostatin resistance; therefore, the regulatory system is producing more enterostatin to counteract the resistance. This is very similar to hyperinsulinemia and hyperleptinemia in obesity. The diminution in the meal-induced secretion of enterostatin in obesity suggests a delay in the appearance of satiety, leading to increased caloric intake. In rats enterostatin decreases body weight by decreasing fat-calorie intake and increasing the sympathetic firing rate of the nerves in interscapular brown adipose tissue. Enterostatin levels are elevated in the plasma of obese women, and enterostatin secretion is diminished after satiety. Oral administration of enterostatin, however, has no effect on food intake, energy expenditure, or body weight in subjects with a preference for a high-fat diet experiencing a negative energy and fat balance, and the physiology of enterostatin in humans remains to be defined. (PMID: 10084574, 9526102, 8886249).
Methyl (2-((R)-(3-chlorophenyl)((R)-1-(((S)-2-(methylamino)-3-((R)-tetrahydro-2H-pyran-3-yl)propyl)carbamoyl)piperidin-3-yl)methoxy)ethyl)carbamate
Falecalcitriol
C27H38F6O3 (524.2724989999999)
Sucrose laurate
Sucrose monolaurate
Sucrose, 1-laurate
Okaramine C
An indole alkaloid isolated from Penicillium simplicissimum. It exhibits insecticidal activity.
(3E,7E,11E,15E)-5,9,13,17,18-pentahydroxy-4,6,8,10-tetramethyl-2-[(E)-2-methylbut-2-enyl]nonadeca-3,7,11,15-tetraenedioic acid
2beta,3alpha,14alpha,16-Tetraacetoxy-15beta-hydroxy-ent-pimarane
21-(carboxyacetoxy)lanosta-7,9(11),24-trien-3-one|fomitopsic acid B
(1R,3aS,5R,10aS,11aS,13aR)-1,2,3,3a,3b,4,5,5a,6,12,13,13a-dodecahydro-3a,6,6,13a-tetramethyl-1-[(1S)-1-((2S)-5-methyl-6-oxo-3,6-dihydro-2H-pyran-2-yl)ethyl]-8-oxo-8H-cyclopenta[5,6]cyclopropa[1,8a]naphtho[2,1-c]oxepin-5-yl acetate|schisanbilactone A
5alpha-cholest-7-ene-2alpha,3beta,5alpha,6beta,9alpha,11alpha,19-heptol 11-acetate
2alpha-acetyloxy-4beta-hydroxy-6alpha-angeloyloxy-10beta-cinnamoyloxydauc-8-ene|2??-Acetoxy-4??-hydroxy-6??-angeloyloxy-10??-cinnamoyloxy-dauc-8-ene
16-O-acetylpolyporenic acid C|16alpha-Acetoxy-24-methylen-3-oxo-lanosta-7,9(11)-dien-21-saeure|16alpha-acetoxy-24-methylene-3-oxolanosta-7,9(11)-dien-21-oic acid|16alpha-acetoxy-3-oxo-eburica-7,9(11),24(28)-trien-21-oic acid|16alpha-Acetoxy-3-oxo-eburica-7,9(11),24(28)-trien-21-saeure|16alpha-acetyloxy-24-methylene-3-oxo-5alpha-lanost-7,9(11)-dien-21-oic acid|16alpha-acetyloxy-24-methylene-3-oxo-lanosta-7,9(11)-dien-21-oic acid
3-O-Acetyl-methyl-(24E)-3??,16??,23??(=16R,23R)-trihydroxy-epoxy-17,14-friedolan-8,14,24-trien-26-oate
(E)-N-[2-(4-hydroxyphenyl)ethyl]-22alpha,23alpha-epoxy-solanida-1,4,9-trien-3-imine
16-acetoxy-22alpha-hydroxy-29-nor-24-methylcycloart-1,4, 24(24a)-trien-3,23-dion-3,4-lactone|4-methylene-neomacrolactone
(21R,23S)-3,26-dioxo-21,23:23,26-diepoxylanosta-8,24-dien-21-yl acetate|omphalocarpoidone
24-acetoxy-18alpha-hydroxy-A(1)-norlupa-2,20(29)-diene-27,28-diolic acid 28-methyl ester 27,18alpha-lactone
13alpha-acetoxy-5-alpha-cinnamoyloxy-11(15-1)abeotaxa-4(20),11-diene-9alpha,10beta,15-triol
12alpha-chloro-2alpha,3beta,13beta,23-tetrahydroxyolean-28-oic acid-13-lactone
(1R*,2R*,3E,7R*,11R*,12S*)-2-O-acetyl-16-O-(3-hydroxy-3-methylglutaryl)-dolabella-3,8(17)-dien-2,7,16,18-tetrol
11-Ac-(2alpha, 3beta, 5alpha, 6beta, 11alpha)-Cholest-7-ene-2, 3, 5, 6, 9, 11, 19-heptol
[3-methyl-1-[3-methyl-1-oxo-1-(2,3,4,5,6-pentahydroxyhexoxy)pentan-2-yl]oxy-1-oxopentan-2-yl] 2-hydroxy-3-methylpentanoate
C31H40O7_3,9-Diacetoxy-2,6,6,13-tetramethyl-12-oxotetracyclo[11.2.1.0~1,10~.0~2,7~]hexadec-8-yl benzoate
[3-methyl-1-[3-methyl-1-oxo-1-(2,3,4,5,6-pentahydroxyhexoxy)pentan-2-yl]oxy-1-oxopentan-2-yl] 2-hydroxy-3-methylpentanoate [IIN-based on: CCMSLIB00000846977]
[3-methyl-1-[3-methyl-1-oxo-1-(2,3,4,5,6-pentahydroxyhexoxy)pentan-2-yl]oxy-1-oxopentan-2-yl] 2-hydroxy-3-methylpentanoate [IIN-based: Match]
(3E,7E,11E,15E)-5,9,13,17,18-pentahydroxy-4,6,8,10-tetramethyl-2-[(E)-2-methylbut-2-enyl]nonadeca-3,7,11,15-tetraenedioic acid_minor
(3E,7E,11E,15E)-5,9,13,17,18-pentahydroxy-4,6,8,10-tetramethyl-2-[(E)-2-methylbut-2-enyl]nonadeca-3,7,11,15-tetraenedioic acid_major
Cys Phe Lys Lys
C24H40N6O5S (524.2780750000001)
Cys Lys Phe Lys
C24H40N6O5S (524.2780750000001)
Cys Lys Lys Phe
C24H40N6O5S (524.2780750000001)
Phe Cys Lys Lys
C24H40N6O5S (524.2780750000001)
Phe Phe Ile Val
Phe Phe Leu Val
Phe Phe Val Ile
Phe Phe Val Leu
Phe Ile Phe Val
Phe Ile Val Phe
Phe Lys Cys Lys
C24H40N6O5S (524.2780750000001)
Phe Lys Lys Cys
C24H40N6O5S (524.2780750000001)
Phe Leu Phe Val
Phe Leu Val Phe
Phe Val Phe Ile
Phe Val Phe Leu
Phe Val Ile Phe
Phe Val Leu Phe
Gly His Arg Arg
Gly Arg His Arg
Gly Arg Arg His
His Gly Arg Arg
His Ile Lys Lys
C24H44N8O5 (524.3434493999999)
His Ile Lys Gln
C23H40N8O6 (524.3070660000001)
His Ile Gln Lys
C23H40N8O6 (524.3070660000001)
His Lys Ile Lys
C24H44N8O5 (524.3434493999999)
His Lys Ile Gln
C23H40N8O6 (524.3070660000001)
His Lys Lys Ile
C24H44N8O5 (524.3434493999999)
His Lys Lys Leu
C24H44N8O5 (524.3434493999999)
His Lys Leu Lys
C24H44N8O5 (524.3434493999999)
His Lys Leu Gln
C23H40N8O6 (524.3070660000001)
His Lys Gln Ile
C23H40N8O6 (524.3070660000001)
His Lys Gln Leu
C23H40N8O6 (524.3070660000001)
His Leu Lys Lys
C24H44N8O5 (524.3434493999999)
His Leu Lys Gln
C23H40N8O6 (524.3070660000001)
His Leu Gln Lys
C23H40N8O6 (524.3070660000001)
His Asn Arg Val
His Asn Val Arg
His Gln Ile Lys
C23H40N8O6 (524.3070660000001)
His Gln Lys Ile
C23H40N8O6 (524.3070660000001)
His Gln Lys Leu
C23H40N8O6 (524.3070660000001)
His Gln Leu Lys
C23H40N8O6 (524.3070660000001)
His Arg Gly Arg
His Arg Asn Val
His Arg Arg Gly
His Arg Val Asn
His Val Asn Arg
His Val Arg Asn
Ile Phe Phe Val
Ile Phe Val Phe
Ile His Lys Lys
C24H44N8O5 (524.3434493999999)
Ile His Lys Gln
C23H40N8O6 (524.3070660000001)
Ile His Gln Lys
C23H40N8O6 (524.3070660000001)
Ile Lys His Lys
C24H44N8O5 (524.3434493999999)
Ile Lys His Gln
C23H40N8O6 (524.3070660000001)
Ile Lys Lys His
C24H44N8O5 (524.3434493999999)
Ile Lys Gln His
C23H40N8O6 (524.3070660000001)
Ile Gln His Lys
C23H40N8O6 (524.3070660000001)
Ile Gln Lys His
C23H40N8O6 (524.3070660000001)
Ile Val Phe Phe
Lys Cys Phe Lys
C24H40N6O5S (524.2780750000001)
Lys Cys Lys Phe
C24H40N6O5S (524.2780750000001)
Lys Phe Cys Lys
C24H40N6O5S (524.2780750000001)
Lys Phe Lys Cys
C24H40N6O5S (524.2780750000001)
Lys His Ile Lys
C24H44N8O5 (524.3434493999999)
Lys His Ile Gln
C23H40N8O6 (524.3070660000001)
Lys His Lys Ile
C24H44N8O5 (524.3434493999999)
Lys His Lys Leu
C24H44N8O5 (524.3434493999999)
Lys His Leu Lys
C24H44N8O5 (524.3434493999999)
Lys His Leu Gln
C23H40N8O6 (524.3070660000001)
Lys His Gln Ile
C23H40N8O6 (524.3070660000001)
Lys His Gln Leu
C23H40N8O6 (524.3070660000001)
Lys Ile His Lys
C24H44N8O5 (524.3434493999999)
Lys Ile His Gln
C23H40N8O6 (524.3070660000001)
Lys Ile Lys His
C24H44N8O5 (524.3434493999999)
Lys Ile Gln His
C23H40N8O6 (524.3070660000001)
Lys Lys Cys Phe
C24H40N6O5S (524.2780750000001)
Lys Lys Phe Cys
C24H40N6O5S (524.2780750000001)
Lys Lys His Ile
C24H44N8O5 (524.3434493999999)
Lys Lys His Leu
C24H44N8O5 (524.3434493999999)
Lys Lys Ile His
C24H44N8O5 (524.3434493999999)
Lys Lys Leu His
C24H44N8O5 (524.3434493999999)
Lys Lys Ser Tyr
Lys Lys Tyr Ser
Lys Leu His Lys
C24H44N8O5 (524.3434493999999)
Lys Leu His Gln
C23H40N8O6 (524.3070660000001)
Lys Leu Lys His
C24H44N8O5 (524.3434493999999)
Lys Leu Gln His
C23H40N8O6 (524.3070660000001)
Lys Gln His Ile
C23H40N8O6 (524.3070660000001)
Lys Gln His Leu
C23H40N8O6 (524.3070660000001)
Lys Gln Ile His
C23H40N8O6 (524.3070660000001)
Lys Gln Leu His
C23H40N8O6 (524.3070660000001)
Lys Ser Lys Tyr
Lys Ser Tyr Lys
Lys Tyr Lys Ser
Lys Tyr Ser Lys
Leu Phe Phe Val
Leu Phe Val Phe
Leu His Lys Lys
C24H44N8O5 (524.3434493999999)
Leu His Lys Gln
C23H40N8O6 (524.3070660000001)
Leu His Gln Lys
C23H40N8O6 (524.3070660000001)
Leu Lys His Lys
C24H44N8O5 (524.3434493999999)
Leu Lys His Gln
C23H40N8O6 (524.3070660000001)
Leu Lys Lys His
C24H44N8O5 (524.3434493999999)
Leu Lys Gln His
C23H40N8O6 (524.3070660000001)
Leu Gln His Lys
C23H40N8O6 (524.3070660000001)
Leu Gln Lys His
C23H40N8O6 (524.3070660000001)
Leu Val Phe Phe
Asn His Arg Val
Asn His Val Arg
Asn Arg His Val
Asn Arg Val His
Asn Val His Arg
Asn Val Arg His
Pro Pro Arg Arg
Pro Arg Pro Arg
Pro Arg Arg Pro
Gln His Ile Lys
C23H40N8O6 (524.3070660000001)
Gln His Lys Ile
C23H40N8O6 (524.3070660000001)
Gln His Lys Leu
C23H40N8O6 (524.3070660000001)
Gln His Leu Lys
C23H40N8O6 (524.3070660000001)
Gln Ile His Lys
C23H40N8O6 (524.3070660000001)
Gln Ile Lys His
C23H40N8O6 (524.3070660000001)
Gln Lys His Ile
C23H40N8O6 (524.3070660000001)
Gln Lys His Leu
C23H40N8O6 (524.3070660000001)
Gln Lys Ile His
C23H40N8O6 (524.3070660000001)
Gln Lys Leu His
C23H40N8O6 (524.3070660000001)
Gln Leu His Lys
C23H40N8O6 (524.3070660000001)
Gln Leu Lys His
C23H40N8O6 (524.3070660000001)
Arg Gly His Arg
Arg Gly Arg His
Arg His Gly Arg
Arg His Asn Val
Arg His Arg Gly
Arg His Val Asn
Arg Asn His Val
Arg Asn Val His
Arg Pro Pro Arg
Arg Pro Arg Pro
Arg Arg Gly His
Arg Arg His Gly
Arg Arg Pro Pro
Arg Val His Asn
Arg Val Asn His
Ser Lys Lys Tyr
Ser Lys Tyr Lys
Ser Tyr Lys Lys
Val Phe Phe Ile
Val Phe Phe Leu
Val Phe Ile Phe
Val Phe Leu Phe
Val His Asn Arg
Val His Arg Asn
Val Ile Phe Phe
Val Leu Phe Phe
Val Asn His Arg
Val Asn Arg His
Val Arg His Asn
Val Arg Asn His
Tyr Lys Lys Ser
Tyr Lys Ser Lys
Tyr Ser Lys Lys
(5Z,7E)-(1S,3R)-26,26,26,27,27,27-hexafluoro-9,10-seco-5,7,10(19)-cholestatriene-1,3,24-triol
C27H38F6O3 (524.2724989999999)
(5Z,7E)-(1S,3R)-26,26,26,27,27,27-hexafluoro-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
C27H38F6O3 (524.2724989999999)
VPGPR Enterostatin
C23H40N8O6 (524.3070660000001)
Synthetic Ligand of FKBP
3,9-Diacetoxy-2,6,6,13-tetramethyl-12-oxotetracyclo[11.2.1.01,10.02,7]hexadec-8-yl benzoate
26,26,26,27,27,27-hexafluoro-1alpha,24-dihydroxyvitamin D3
26,26,26,27,27,27-hexafluoro-1alpha,25-dihydroxyvitamin D3
VTP-27999
alpha-d-Glucopyranoside, beta-d-fructofuranosyl, dodecanoate
Falecalcitriol
C27H38F6O3 (524.2724989999999)
D018977 - Micronutrients > D014815 - Vitamins > D004100 - Dihydroxycholecalciferols D018977 - Micronutrients > D014815 - Vitamins > D006887 - Hydroxycholecalciferols D003879 - Dermatologic Agents
22-[(2R)-1-hydroxy-3-phosphonooxypropan-2-yl]oxy-22-oxodocosanoic acid
(5Z)-5-[(2E)-2-[7a-methyl-1-[7,7,7-trifluoro-6-hydroxy-6-(trifluoromethyl)heptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
C27H38F6O3 (524.2724989999999)
tert-butyl 4-ethyl-4-[[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]pentan-2-yl]carbamoyloxy]piperidine-1-carboxylate
C26H44N4O7 (524.3209833999999)
N-(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl-sn-glycero-3-phosphoethanolamine(1-)
(3S)-3beta-[2-(1,1-Dimethyl-2-propenyl)-1H-indole-3-ylmethyl]-6-(1,1-dimethyl-2-propenyl)-2,3,4,5aalpha,6,10b,11,11aalpha-octahydro-10balpha-hydroxy-1H-pyrazino[1,2:1,5]pyrrolo[2,3-b]indole-1,4-dione
N-[(4R,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(pyridin-3-ylmethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]oxane-4-carboxamide
1-[(4R,7R,8R)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-(3-methoxyphenyl)urea
1-[(4R,7R,8S)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-(3-methoxyphenyl)urea
1-[(4R,7S,8S)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-(3-methoxyphenyl)urea
N-[(4S,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(pyridin-3-ylmethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]oxane-4-carboxamide
1-[(4S,7R,8R)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-(3-methoxyphenyl)urea
1-[(4S,7R,8S)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-(3-methoxyphenyl)urea
[3-Methyl-1-[3-methyl-1-oxo-1-(2,3,4,5,6-pentahydroxyhexoxy)pentan-2-yl]oxy-1-oxopentan-2-yl] 2-hydroxy-3-methylpentanoate
N-[(4S,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(3-pyridinylmethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide
N-[(4S,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(3-pyridinylmethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide
N-[(4S,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(3-pyridinylmethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide
N-[(4R,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(3-pyridinylmethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide
N-[(4R,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(3-pyridinylmethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide
N-[(4R,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(3-pyridinylmethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide
1-[(4S,7S,8S)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-(3-methoxyphenyl)urea
1-[(4R,7S,8R)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-(3-methoxyphenyl)urea
(2R)-4-amino-2-[3-[[(3R,5R,7S,8E,10E,12E)-3-amino-5-hydroxy-7-methoxyoctadeca-8,10,12-trienoyl]amino]propanoylamino]-4-oxobutanoic acid
C26H44N4O7 (524.3209833999999)
2-[[(2Z,5Z)-6-[[(2E,4E,10E)-7,9-dimethoxy-3,6,8-trimethyl-11-phenylundeca-2,4,10-trienoyl]amino]hexa-2,5-dienoyl]amino]acetic acid
2,3-dihydroxypropyl [2-hydroxy-3-[(Z)-icos-11-enoxy]propyl] hydrogen phosphate
[3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (Z)-nonadec-9-enoate
[1-[(2-acetyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (Z)-hexadec-9-enoate
C24H45O10P (524.2750199999999)
[1-hydroxy-3-[hydroxy-(3-hydroxy-2-propanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (Z)-pentadec-9-enoate
C24H45O10P (524.2750199999999)
[1-[(2-butanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (Z)-tetradec-9-enoate
C24H45O10P (524.2750199999999)
[1-hydroxy-3-[hydroxy-(3-hydroxy-2-pentanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (Z)-tridec-9-enoate
C24H45O10P (524.2750199999999)
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-pentanoyloxypropan-2-yl] (Z)-tridec-9-enoate
C24H45O10P (524.2750199999999)
[1-butanoyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (Z)-tetradec-9-enoate
C24H45O10P (524.2750199999999)
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] (Z)-pentadec-9-enoate
C24H45O10P (524.2750199999999)
[1-acetyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (Z)-hexadec-9-enoate
C24H45O10P (524.2750199999999)
[3-hydroxy-2-[(5E,8E,11E)-tetradeca-5,8,11-trienoyl]oxypropyl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate
2-[(2-Decanoyloxy-3-heptanoyloxypropoxy)-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[(3-Acetyloxy-2-pentadecanoyloxypropoxy)-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[(3-Butanoyloxy-2-tridecanoyloxypropoxy)-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[(3-Hexanoyloxy-2-undecanoyloxypropoxy)-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[Hydroxy-(3-propanoyloxy-2-tetradecanoyloxypropoxy)phosphoryl]oxyethyl-trimethylazanium
2-[(2-Dodecanoyloxy-3-pentanoyloxypropoxy)-hydroxyphosphoryl]oxyethyl-trimethylazanium
[1-carboxy-3-[2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-3-propanoyloxypropoxy]propyl]-trimethylazanium
C29H50NO7+ (524.3587090000001)
2-[Hydroxy-(2-nonanoyloxy-3-octanoyloxypropoxy)phosphoryl]oxyethyl-trimethylazanium
1-(1Z-eicosenyl)-glycero-3-phospho-(1-sn-glycerol)
1-(9Z-nonadecenoyl)-glycero-3-phospho-(1-sn-glycerol)
BIBS 39
BIBS 39 is a new nonpeptide angiotensin II (AII) receptor antagonist. Target: Angiotensin Receptor in vitro: BIBS 39 displaces [125I] AII from its specific binding sites with a Ki value of 29 ± 7 nM for the AII subtype 1 (AT1) receptor and a Ki value of 480 ± 110 nM for the AII subtype 2 (AT2) receptor. BIBS 222 shows a Ki value of 20 ± 7 nM for the AT1 subtype and a Ki value of 730 ± 170 nM for the AT2 subtype. BIBS 39 is 17 times more selective for the AT1 subtype and BIBS 222 37 times. BIBS 39 shifts the AII concentration-contractile response curves in isolated rabbit aorta to the right in a parallel fashion. [1] in vivo: In pithed rats, BIBS 39 dependently shifts the dose-response curve of AII to the right without affecting the maximal response. BIBS 222 also causes parallel shifts to the right but a significant reduction of the maximal responses was observed at 3 and 10 mg/kg i.v. These results show that the benzimidazole derivatives BIBS 39 is a potent and selective AII receptor antagonists. Substitution with a benzimidazole moiety results into a considerable loss of selectivity for the AT1 receptor subtype compared with an imidazole moiety as, for instance, in DuP 753.[1] BIBS 39 is a new nonpeptide angiotensin receptor blockers that has affinity for both AT1- and AT2-receptors, is also a potent antagonist of the cardiovascular effects of AII in pithed rabbits. [2]